World's Best Scientists 2026 revealed!
Diane Provencher

Diane Provencher

D-Index & Metrics

Medicine

D-Index
74
Citations
25181
World Ranking
19315
National Ranking
817

Overview

Diane Provencher is affiliated with the University of Montreal in Canada and has a research focus predominantly in Medicine and Biochemistry, Genetics, and Molecular Biology. Their work spans several key subfields including Oncology, Reproductive Medicine, Molecular Biology, Genetics, and Immunology.

The scientist's research topics are primarily centered on ovarian cancer diagnosis and treatment, PARP inhibition in cancer therapy, BRCA gene mutations in cancer, endometrial and cervical cancer treatments, cancer immunotherapy and biomarkers, CRISPR and genetic engineering, and sarcoma diagnosis and treatment.

Frequent co-authors of Diane Provencher include Anne-Marie Mes-Masson, David M. O'Malley, Amit M. Oza, Ana Oaknin, and Lucy Gilbert.

The main publication venues for their research have been:

  • Gynecologic Oncology
  • Journal of Clinical Oncology
  • bioRxiv (Cold Spring Harbor Laboratory)
  • International Journal of Gynecological Cancer
  • Scientific Reports

Among the recent papers authored or co-authored by Diane Provencher are:

  • Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial (2021, The Lancet Oncology)
  • A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45) (2022, Journal of Clinical Oncology)
  • Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial (2023, Journal of Clinical Oncology)
  • Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2) (2021, Nature Communications)
  • Uterine serous carcinoma (2021, Gynecologic Oncology)

Best Publications

  • Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

    Eric Pujade-Lauraine;Jonathan A Ledermann;Frédéric Selle;Val Gebski

  • ARID1A mutations in endometriosis-associated ovarian carcinomas.

    Kimberly C. Wiegand;Sohrab P. Shah;Osama M. Al-Agha;Yongjun Zhao

  • Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

    Robert L Coleman;Amit M Oza;Domenica Lorusso;Carol Aghajanian

  • Oral Contraceptives and the Risk of Hereditary Ovarian Cancer

    S. A. Narod;H. Risch;R. Moslehi;A. Dorum

  • Mutation of FOXL2 in Granulosa-Cell Tumors of the Ovary

    Sohrab P Shah;Martin Köbel;Janine Senz;Ryan D Morin

  • 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004).

    A du Bois;M Quinn;T Thigpen;J Vermorken

  • Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial

    Stephanie M. de Boer;Melanie E. Powell;Linda Mileshkin;Dionyssios Katsaros

  • Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study

    U.A. Matulonis;R. Shapira-Frommer;A.D. Santin;A.S. Lisyanskaya

  • Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial

    Stephanie M de Boer;Melanie E Powell;Linda Mileshkin;Dionyssios Katsaros

  • Phase II Study of Temsirolimus in Women With Recurrent or Metastatic Endometrial Cancer: A Trial of the NCIC Clinical Trials Group

    Amit M. Oza;Laurie Elit;Ming-Sound Tsao;Suzanne Kamel-Reid

  • Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial

    Bradley J. Monk;Andrés Poveda;Ignace Vergote;Francesco Raspagliesi

  • Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2

    Amit M. Oza;Anna V. Tinker;Ana Oaknin;Ronnie Shapira-Frommer

  • Sentinel nodes in vulvar cancer: Long-term follow-up of the GROningen INternational Study on Sentinel nodes in Vulvar cancer (GROINSS-V) I.

    te Nienke Grootenhuis;van der Ate Zee;H. C. van Doorn;J. van der Velden

  • Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes

    Yi Kan Wang;Ali Bashashati;Michael S Anglesio;Dawn R Cochrane

  • Molecular description of a 3D in vitro model for the study of epithelial ovarian cancer (EOC).

    Magdalena Zietarska;Christine M. Maugard;Christine M. Maugard;Abdelali Filali-Mouhim;Mona Alam-Fahmy

  • CD73 Is Associated with Poor Prognosis in High-Grade Serous Ovarian Cancer

    Martin Turcotte;Kathleen Spring;Sandra Pommey;Guillaume Chouinard

  • Randomized, Double-Blind, Placebo-Controlled Phase II Study of AMG 386 Combined With Weekly Paclitaxel in Patients With Recurrent Ovarian Cancer

    Beth Y. Karlan;Amit M. Oza;Gary E. Richardson;Diane M. Provencher

  • Clinical trials in recurrent ovarian cancer.

    Michael Friedlander;Edward Trimble;Anna Tinker;David Alberts

  • CHARACTERIZATION OF FOUR NOVEL EPITHELIAL OVARIAN CANCER CELL LINES

    D. M. Provencher;H. Lounis;L. Champoux;M. Tétrault

  • An Immunohistochemical Algorithm for Ovarian Carcinoma Typing.

    Martin Köbel;Kurosh Rahimi;Peter F. Rambau;Christopher Naugler;Christopher Naugler

Frequent Co-Authors

Patricia N. Tonin
Patricia N. Tonin McGill University
Anne-Marie Mes-Masson
Anne-Marie Mes-Masson University of Montreal
William D. Foulkes
William D. Foulkes McGill University
Amit M. Oza
Amit M. Oza Princess Margaret Cancer Centre
Ana Oaknin
Ana Oaknin Vall d'Hebron Hospital Universitari
Isabelle Ray-Coquard
Isabelle Ray-Coquard Claude Bernard University Lyon 1
Steven A. Narod
Steven A. Narod University of Toronto
Martin Köbel
Martin Köbel University of Calgary
Ursula A. Matulonis
Ursula A. Matulonis Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Prospective medical professionals have a wide range of online academic pathways to launch or advance their careers in healthcare. Many students start by comparing the phd nursing programs offered online, which are ideal for those interested in research, teaching, or high-level clinical roles.

For registered nurses intending to elevate their credentials, exploring the cheapest accredited online rn to bsn programs can make earning a bachelor's degree accessible and affordable. These programs often offer flexible schedules for busy healthcare professionals.

Those without a nursing background but eager to make a direct entry into the field should consider entry level msn programs online. Such options are designed for non-nurses seeking a fast-track into advanced nursing careers.

If cost or admissions requirements are concerns, students can look for the easiest bsn program to get into. These programs can provide more accessible entry points into nursing and help address the ongoing demand for qualified professionals in the field.

Best Scientists Citing Diane Provencher

Trending Scientists